LURAP1: A Potential Drug Target and Biomarker (G541468)

Target Name: LURAP1

NCBI ID: G541468

LURAP1

LURAP1: A Potential Drug Target and Biomarker

LURAP1 (Luteinuronic Acid Phosphate 1) is a protein that is expressed in various tissues, including the liver, pancreas, and gastrointestinal tract. It is involved in the regulation of cell signaling pathways, including the TGF-β pathway. TGF-β is a well-known protein that plays a crucial role in cell growth, differentiation, and repair. The TGF-β pathway is a complex signaling pathway that is involved in many physiological processes in the body, including cell growth, differentiation, and regeneration.

Recent studies have identified LURAP1 as a potential drug target and biomarker for several diseases, including cancer, insulin resistance, and neurodegenerative diseases. In this article, we will explore the biology of LURAP1 and its potential as a drug target and biomarker.

Biomarker Potential

LURAP1 has been identified as a potential biomarker for several diseases, including cancer, insulin resistance, and neurodegenerative diseases. One of the main reasons for its potential as a biomarker is its expression in various tissues, including the liver, pancreas, and gastrointestinal tract. This makes it a potential biomarker for a wide range of diseases.

In cancer, LURAP1 has been shown to be involved in the regulation of cell signaling pathways, including the TGF-β pathway. TGF-β is a well-known protein that plays a crucial role in cell growth, differentiation, and repair. The TGF-β pathway is a complex signaling pathway that is involved in many physiological processes in the body, including cell growth, differentiation, and regeneration. Therefore, changes in the expression of LURAP1 have been observed in various types of cancer.

In insulin resistance, LURAP1 has been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway. Insulin resistance is a condition in which the body's cells become less responsive to insulin, making it difficult for the body to maintain normal blood sugar levels. LURAP1 has been shown to be involved in the regulation of insulin sensitivity, and therefore, changes in its expression have been observed in individuals with insulin resistance.

In neurodegenerative diseases, LURAP1 has been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway. Neurodegenerative diseases are a group of conditions that are characterized by the progressive loss of brain cells and their functions. LURAP1 has been shown to be involved in the regulation of neurodegenerative diseases, and therefore, changes in its expression have been observed in individuals with neurodegenerative diseases.

Drug Target Potential

LURAP1 has also been identified as a potential drug target for several diseases, including cancer, insulin resistance, and neurodegenerative diseases. One of the main reasons for its potential as a drug target is its involvement in the TGF-β pathway. TGF-β is a well-known protein that plays a crucial role in cell growth, differentiation, and repair. Therefore, drugs that can inhibit TGF-β signaling pathways, including LURAP1, have been shown to be effective in treating several diseases.

In cancer, LURAP1 has been shown to be involved in the regulation of cell signaling pathways, including the TGF-β pathway. Therefore, drugs that can inhibit TGF-β signaling pathways, including LURAP1, have been shown to be effective in treating various types of cancer. For example, a drug called ALIMOPLAN has been shown to be effective in treating colorectal cancer by inhibiting TGF-β signaling pathways.

In insulin resistance, LURAP1 has been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway. Therefore, drugs

Protein Name: Leucine Rich Adaptor Protein 1

Functions: Acts as an activator of the canonical NF-kappa-B pathway and drive the production of pro-inflammatory cytokines. Promotes the antigen (Ag)-presenting and priming function of dendritic cells via the canonical NF-kappa-B pathway (PubMed:21048106). In concert with MYO18A and CDC42BPA/CDC42BPB, is involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration. Activates CDC42BPA/CDC42BPB and targets it to actomyosin through its interaction with MYO18A, leading to MYL9/MLC2 phosphorylation and MYH9/MYH10-dependent actomyosin assembly in the lamella (By similarity)

The "LURAP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LURAP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets